Heterogeneity derived from 18 F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patients.
Yizhao XieCheng LiuYannan ZhaoChengcheng GongYi LiShihui HuShaoli SongXi-Chun HuZhongyi YangBi-Yun WangPublished in: Cancer medicine (2022)
F-FDG PET/CT could represent a simple and promising predictor for first-line immunotherapy among mTNBC patients.